FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080241308> ?p ?o ?g. }

• W3080241308 endingPage "752" @default.
• W3080241308 startingPage "752" @default.
• W3080241308 abstract "<h3>Importance</h3> Severe asthma exacerbations cause significant morbidity and costs. Whether vitamin D₃supplementation reduces severe childhood asthma exacerbations is unclear. <h3>Objective</h3> To determine whether vitamin D₃supplementation improves the time to a severe exacerbation in children with asthma and low vitamin D levels. <h3>Design, Setting, and Participants</h3> The Vitamin D to Prevent Severe Asthma Exacerbations (VDKA) Study was a randomized, double-blind, placebo-controlled clinical trial of vitamin D₃supplementation to improve the time to severe exacerbations in high-risk children with asthma aged 6 to 16 years taking low-dose inhaled corticosteroids and with serum 25-hydroxyvitamin D levels less than 30 ng/mL. Participants were recruited from 7 US centers. Enrollment started in February 2016, with a goal of 400 participants; the trial was terminated early (March 2019) due to futility, and follow-up ended in September 2019. <h3>Interventions</h3> Participants were randomized to vitamin D₃, 4000 IU/d (n = 96), or placebo (n = 96) for 48 weeks and maintained with fluticasone propionate, 176 μg/d (6-11 years old), or 220 μg/d (12-16 years old). <h3>Main Outcomes and Measures</h3> The primary outcome was the time to a severe asthma exacerbation. Secondary outcomes included the time to a viral-induced severe exacerbation, the proportion of participants in whom the dose of inhaled corticosteroid was reduced halfway through the trial, and the cumulative fluticasone dose during the trial. <h3>Results</h3> Among 192 randomized participants (mean age, 9.8 years; 77 girls [40%]), 180 (93.8%) completed the trial. A total of 36 participants (37.5%) in the vitamin D₃group and 33 (34.4%) in the placebo group had 1 or more severe exacerbations. Compared with placebo, vitamin D₃supplementation did not significantly improve the time to a severe exacerbation: the mean time to exacerbation was 240 days in the vitamin D₃group vs 253 days in the placebo group (mean group difference, −13.1 days [95% CI, −42.6 to 16.4]; adjusted hazard ratio, 1.13 [95% CI, 0.69 to 1.85];<i>P</i> = .63). Vitamin D₃supplementation, compared with placebo, likewise did not significantly improve the time to a viral-induced severe exacerbation, the proportion of participants whose dose of inhaled corticosteroid was reduced, or the cumulative fluticasone dose during the trial. Serious adverse events were similar in both groups (vitamin D₃group, n = 11; placebo group, n = 9). <h3>Conclusions and Relevance</h3> Among children with persistent asthma and low vitamin D levels, vitamin D₃supplementation, compared with placebo, did not significantly improve the time to a severe asthma exacerbation. The findings do not support the use of vitamin D₃supplementation to prevent severe asthma exacerbations in this group of patients. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT02687815" @default.
• W3080241308 created "2020-09-01" @default.
• W3080241308 creator A5004616748 @default.
• W3080241308 creator A5005697326 @default.
• W3080241308 creator A5012068668 @default.
• W3080241308 creator A5013823897 @default.
• W3080241308 creator A5024561283 @default.
• W3080241308 creator A5043557072 @default.
• W3080241308 creator A5043763838 @default.
• W3080241308 creator A5044705183 @default.
• W3080241308 creator A5057890262 @default.
• W3080241308 creator A5059864993 @default.
• W3080241308 creator A5062088708 @default.
• W3080241308 creator A5086541936 @default.
• W3080241308 creator A5087138210 @default.
• W3080241308 creator A5088060708 @default.
• W3080241308 date "2020-08-25" @default.
• W3080241308 modified "2023-10-05" @default.
• W3080241308 title "Effect of Vitamin D₃ Supplementation on Severe Asthma Exacerbations in Children With Asthma and Low Vitamin D Levels" @default.
• W3080241308 cites W1866685620 @default.
• W3080241308 cites W1971145825 @default.
• W3080241308 cites W1972784839 @default.
• W3080241308 cites W1996282132 @default.
• W3080241308 cites W2043387305 @default.
• W3080241308 cites W2068514997 @default.
• W3080241308 cites W2078372877 @default.
• W3080241308 cites W2106449126 @default.
• W3080241308 cites W2108678383 @default.
• W3080241308 cites W2114301704 @default.
• W3080241308 cites W2116151144 @default.
• W3080241308 cites W2125078269 @default.
• W3080241308 cites W2134744881 @default.
• W3080241308 cites W2146420833 @default.
• W3080241308 cites W2254958366 @default.
• W3080241308 cites W2553590861 @default.
• W3080241308 cites W2601675613 @default.
• W3080241308 cites W2616424562 @default.
• W3080241308 cites W2763472604 @default.
• W3080241308 cites W2907270550 @default.
• W3080241308 cites W2921155200 @default.
• W3080241308 cites W2954442935 @default.
• W3080241308 cites W3005399372 @default.
• W3080241308 cites W4241064091 @default.
• W3080241308 doi "https://doi.org/10.1001/jama.2020.12384" @default.
• W3080241308 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7448830" @default.
• W3080241308 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32840597" @default.
• W3080241308 hasPublicationYear "2020" @default.
• W3080241308 type Work @default.
• W3080241308 sameAs 3080241308 @default.
• W3080241308 citedByCount "88" @default.
• W3080241308 countsByYear W30802413082020 @default.
• W3080241308 countsByYear W30802413082021 @default.
• W3080241308 countsByYear W30802413082022 @default.
• W3080241308 countsByYear W30802413082023 @default.
• W3080241308 crossrefType "journal-article" @default.
• W3080241308 hasAuthorship W3080241308A5004616748 @default.
• W3080241308 hasAuthorship W3080241308A5005697326 @default.
• W3080241308 hasAuthorship W3080241308A5012068668 @default.
• W3080241308 hasAuthorship W3080241308A5013823897 @default.
• W3080241308 hasAuthorship W3080241308A5024561283 @default.
• W3080241308 hasAuthorship W3080241308A5043557072 @default.
• W3080241308 hasAuthorship W3080241308A5043763838 @default.
• W3080241308 hasAuthorship W3080241308A5044705183 @default.
• W3080241308 hasAuthorship W3080241308A5057890262 @default.
• W3080241308 hasAuthorship W3080241308A5059864993 @default.
• W3080241308 hasAuthorship W3080241308A5062088708 @default.
• W3080241308 hasAuthorship W3080241308A5086541936 @default.
• W3080241308 hasAuthorship W3080241308A5087138210 @default.
• W3080241308 hasAuthorship W3080241308A5088060708 @default.
• W3080241308 hasBestOaLocation W30802413081 @default.
• W3080241308 hasConcept C124490489 @default.
• W3080241308 hasConcept C126322002 @default.
• W3080241308 hasConcept C142724271 @default.
• W3080241308 hasConcept C168563851 @default.
• W3080241308 hasConcept C187212893 @default.
• W3080241308 hasConcept C204787440 @default.
• W3080241308 hasConcept C27081682 @default.
• W3080241308 hasConcept C2776042228 @default.
• W3080241308 hasConcept C2776804153 @default.
• W3080241308 hasConcept C2777014857 @default.
• W3080241308 hasConcept C2779028295 @default.
• W3080241308 hasConcept C2779740938 @default.
• W3080241308 hasConcept C2781212218 @default.
• W3080241308 hasConcept C2909082789 @default.
• W3080241308 hasConcept C71924100 @default.
• W3080241308 hasConceptScore W3080241308C124490489 @default.
• W3080241308 hasConceptScore W3080241308C126322002 @default.
• W3080241308 hasConceptScore W3080241308C142724271 @default.
• W3080241308 hasConceptScore W3080241308C168563851 @default.
• W3080241308 hasConceptScore W3080241308C187212893 @default.
• W3080241308 hasConceptScore W3080241308C204787440 @default.
• W3080241308 hasConceptScore W3080241308C27081682 @default.
• W3080241308 hasConceptScore W3080241308C2776042228 @default.
• W3080241308 hasConceptScore W3080241308C2776804153 @default.
• W3080241308 hasConceptScore W3080241308C2777014857 @default.
• W3080241308 hasConceptScore W3080241308C2779028295 @default.
• W3080241308 hasConceptScore W3080241308C2779740938 @default.
• W3080241308 hasConceptScore W3080241308C2781212218 @default.

• next